Stockreport

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026Strong balance sheet and cash runway into 2028 LOND [Read more]